Global health security as it pertains to Zika, Ebola, and COVID-19

Purpose of review Due to the impact of the COVID-19 pandemic this past year, we have witnessed a significant acceleration in the science, technology, and policy of global health security. This review highlights important progress made toward the mitigation of Zika, Ebola, and COVID-19 outbreaks. These epidemics and their shared features suggest a unified policy and technology agenda that could broadly improve global health security. Recent findings Molecular epidemiology is not yet in widespread use, but shows promise toward informing on-the-ground decision-making during outbreaks. Point-of-care (POC) diagnostics have been achieved for each of these threats; however, deployment of Zika and Ebola diagnostics lags behind those for COVID-19. POC metagenomics offers the possibility of identifying novel viruses. Vaccines have been successfully approved for Ebola and COVID-19, due in large part to public-private partnerships and advance purchase commitments. Therapeutics trials conducted during ongoing epidemics have identified effective antibody therapeutics for Ebola, as well as steroids (both inhaled and oral) and a broad-spectrum antiviral for COVID-19. Summary Achieving global health security remains a challenge, though headway has been made over the past years. Promising policy and technology strategies that would increase resilience across emerging viral pathogens should be pursued.
Source: Current Opinion in Infectious Diseases - Category: Infectious Diseases Tags: TROPICAL AND TRAVEL-ASSOCIATED DISEASES: Edited by Christina M. Coyle Source Type: research

Related Links:

Comp Med. 2021 Oct 5. doi: 10.30802/AALAS-CM-21-000062. Online ahead of print.ABSTRACTThe significant advances made by the global scientific community during the COVID-19 pandemic, exemplified by thedevelopment of multiple SARS-CoV-2 vaccines in less than 1 y, were made possible in part because of animal research.Historically, animals have been used to study the characterization, treatment, and prevention of most of the major infectious disease outbreaks that humans have faced. From the advent of modern 'germ theory' prior to the 1918 Spanish Flu pandemic through the more recent Ebola and Zika virus outbreaks, research tha...
Source: Comparative Medicine - Category: Zoology Authors: Source Type: research
COVID-19 has shown that we need to act fast as changes at the interface of humans, livestock and wildlife are driving increased risk of emerging disease threats across the globe. Credit: Marc-André Boisvert/IPSBy Olanike AdeyemoIBADAN, Nigeria, May 11 2021 (IPS) The COVID-19 pandemic has shown us that global health challenges cannot be solved only by health sector interventions. Many of the recent epidemics — Ebola, Zika and even Covid-19 — are emerging infectious diseases transmissible from wildlife species. In addition, other global health challenges greatly impact people, livestock, wildlife and agri...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Africa Headlines Health TerraViva United Nations Source Type: news
onnac The emergence or re-emergence of viruses with epidemic and/or pandemic potential, such as Ebola, Zika, Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus 1 and 2 (SARS and SARS-CoV-2) viruses, or new strains of influenza represents significant human health threats due to the absence of available treatments. Vaccines represent a key answer to control these viruses. However, in the case of a public health emergency, vaccine development, safety, and partial efficacy concerns may hinder their prompt deployment. Thus, developing broad-spectrum antiviral molecules for a fast resp...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post What Developing Countries Can Teach Us About How To Respond To a Pandemic appeared first on Inter Press Service.
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health TerraViva United Nations Source Type: news
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
The COVID-19 pandemic has had significant global consequences, with healthcare systems stretched to their limits, a growing death toll, and economic devastation as economies came grinding to a halt. The pandemic and its aftereffects will be with u...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Medicine Public Health Source Type: blogs
President Donald Trump’s declaration of a national emergency is designed to speed federal support to parts of America that are struggling to prepare for a coming surge of COVID-19 cases, unlocking $50 billion in aid, giving hospitals and doctors more freedom to handle a potential tsunami of sick patients and scrambling to make tests available. In a Rose Garden press conference Friday, Trump presented the emergency measures as proof that, “No nation is more prepared or more equipped to face down this crisis.” But for epidemiologists, medical experts and current and former U.S. public health officials, the ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
Pandemics are perversely democratic. They’re nasty, lethal and sneaky, but they don’t discriminate. No matter your age, ethnicity, religion, gender, or nation, you’re a part of the pathogenic constituency. That shared vulnerability, and the resulting human collectivism—a universal response to a universal threat—is newly and vividly evident in the face of the now-global outbreak of the novel coronavirus known as 2019-nCoV. As of writing, there have been over 30,000 diagnosed cases and over 630 related deaths. A virus that emerged in a single city, Wuhan, China—indeed, in a single crowded ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV Infectious Disease Source Type: news
“Everyone knows that pestilences have a way of recurring in the world,” observes Albert Camus in his novel The Plague. “Yet somehow we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet plagues and wars always take people by surprise.” Camus was imagining a fictional outbreak of plague in 1948 in Oran, a port city in northwest Algeria. But at a time when the world is reeling from a very real microbial emergency sparked by the emergence of a novel coronavirus in Wuhan, central China, his observations are as pertinent a...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV health ideas Source Type: news
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson &Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing commitmen...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: COVID-19 | Ebola | Ebola Vaccine | Epidemics | Epidemiology | Infectious Diseases | Outbreaks | Pandemics | Partnerships | Science | Vaccines | Zika Virus